Ionis Pharmaceuticals, Inc. (IONS) Financial Statements
Ionis Pharmaceuticals, Inc. (IONS) reported trailing twelve-month revenue of $874.1M (down 7.4% year on year) and net income of -$565.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$560.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IONSIonis Pharmaceuticals, Inc.Follow IONS — free
—
Price chart with a free account
- Market cap
- 7.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.11 | 0.10 | 0.10 | 0.15 | 0.21 | 0.28 | 0.35 | 0.51 | 0.60 | 1.12 | 0.73 | 0.81 | 0.59 | 0.79 | 0.71 | 0.94 | 0.87 | |
| Gross profit | — | — | — | — | — | — | — | — | 0.60 | 1.12 | 0.72 | 0.80 | 0.57 | 0.78 | 0.69 | 0.93 | — | |
| Research & development | 0.15 | 0.15 | 0.15 | 0.17 | 0.24 | 0.32 | 0.34 | 0.37 | 0.41 | 0.46 | 0.53 | 0.64 | — | 0.90 | 0.90 | 0.92 | — | |
| Operating income | -0.05 | -0.07 | -0.07 | -0.05 | -0.05 | -0.08 | -0.02 | 0.03 | -0.06 | 0.37 | -0.17 | -0.03 | -0.41 | -0.35 | -0.48 | -0.38 | -0.59 | |
| Pre-tax income | -0.06 | -0.08 | -0.07 | -0.07 | -0.05 | -0.09 | -0.06 | -0.02 | -0.08 | 0.34 | -0.13 | -0.03 | -0.26 | -0.33 | -0.46 | -0.38 | -0.56 | |
| Income tax | 0.00 | 0.00 | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 | -0.01 | -0.29 | 0.05 | 0.35 | -0.00 | 0.01 | 0.03 | -0.01 | 0.00 | 0.00 | |
| Net income | -0.06 | -0.08 | -0.07 | -0.06 | -0.04 | -0.09 | -0.06 | 0.00 | 0.27 | 0.28 | -0.44 | -0.03 | -0.27 | -0.37 | -0.45 | -0.38 | -0.57 | |
| Diluted EPS ($) | -0.62 | -0.85 | -0.65 | -0.55 | -0.33 | -0.74 | -0.50 | 0.15 | 2.07 | 1.90 | -3.18 | -0.20 | -1.90 | -2.56 | -3.04 | -2.38 | -3.46 | |
| Diluted shares (bn) | 0.099 | 0.100 | 0.101 | 0.111 | — | 0.120 | 0.121 | 0.126 | 0.134 | 0.153 | 0.140 | 0.141 | 0.142 | 0.143 | 0.150 | 0.160 | — |
USD billions · SEC XBRL
Ionis Pharmaceuticals, Inc. — questions
- What is Ionis Pharmaceuticals, Inc.'s revenue?
- $874.1M over the twelve months to 2026-06-30, down 7.4% year on year, from its 10-Q and 10-K filings.
- What is Ionis Pharmaceuticals, Inc.'s net income?
- -$565.2M over the twelve months to 2026-06-30.
- What is Ionis Pharmaceuticals, Inc.'s free cash flow?
- -$560.8M over the twelve months to 2026-06-30.
- What are Ionis Pharmaceuticals, Inc.'s diluted earnings per share?
- $-3.46 over the twelve months to 2026-06-30.
Every figure on this page comes from Ionis Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.